Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 43 tables and 86 figures, this 160-page report “Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Europe biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
o Granulocyte Colony Stimulating Factor
o P53 Protein
o P38 Protein
o Other Purified Proteins
o Amyloid Protein
o Defensin
o Transferrin
o Recombinant Insulin
o Other Recombinant Hormones
? Cancer Vaccines
? Malaria Vaccines
? Ebola Vaccines
? Hepatitis Vaccines
? Tetanus Vaccines
? Diphtheria Vaccines
? Cholera Vaccines
? Other Recombinant Vaccines
o Conventional Vaccines
? Polio Vaccines
? Pox Vaccines
? Other Conventional Vaccines
o Cyclase
o Caspase
o Cathepsin
o Autologous Products
o Acellular Products
o Other Products
Based on Testing Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
Highlighted with 43 tables and 86 figures, this 160-page report “Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Europe biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
- Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
- Recombinant Growth Factors
o Granulocyte Colony Stimulating Factor
- Purified Proteins
o P53 Protein
o P38 Protein
o Other Purified Proteins
- Recombinant Proteins
o Amyloid Protein
o Defensin
o Transferrin
- Recombinant Hormones
o Recombinant Insulin
o Other Recombinant Hormones
- Vaccines
? Cancer Vaccines
? Malaria Vaccines
? Ebola Vaccines
? Hepatitis Vaccines
? Tetanus Vaccines
? Diphtheria Vaccines
? Cholera Vaccines
? Other Recombinant Vaccines
o Conventional Vaccines
? Polio Vaccines
? Pox Vaccines
? Other Conventional Vaccines
- Recombinant Enzymes
o Cyclase
o Caspase
o Cathepsin
- Cell and Gene Therapies
o Autologous Products
o Acellular Products
- Synthetic Immunomodulators
- Other Product Types
o Other Products
Based on Testing Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
- Laboratory Testing
- Custom Testing/Customer Proprietary Testing
- Compendial and Multi Compendial Laboratory Testing
- Formulation Excipients
- Active Pharmaceutical Ingredients (API)
- Other Materials
- Innovative Biopharmaceuticals
- Biogenerics and Biosimilars
- Oncology
- Inflammatory and Infectious Diseases
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders
- Cardiovascular Diseases
- Neurological Diseases
- Other Therapeutic Areas
- Germany
- UK
- France
- Spain
- Italy
- Netherlands
- Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 INTRODUCTION
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.1.3 Impact of Russia-Ukraine Conflict
2.1.4 Impact of Israel-Palestine War
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF EUROPE MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Monoclonal Antibodies
3.2.1 Anti-cancer Monoclonal Antibodies
3.2.2 Anti-inflammatory Monoclonal Antibodies
3.2.3 Other Monoclonal Antibodies
3.3 Recombinant Growth Factors
3.3.1 Erythropoietin
3.3.2 Granulocyte Colony Stimulating Factor
3.4 Purified Proteins
3.4.1 Leukemia Inhibitory Factor (LIF)
3.4.2 P53 Protein
3.4.3 P38 Protein
3.4.4 Other Purified Proteins
3.5 Recombinant Proteins
3.5.1 Serum Albumin
3.5.2 Amyloid Protein
3.5.3 Defensin
3.5.4 Transferrin
3.6 Recombinant Hormones
3.6.1 Recombinant Human Growth Hormones
3.6.2 Recombinant Insulin
3.6.3 Other Recombinant Hormones
3.7 Vaccines
3.7.1 Recombinant Vaccines
3.7.2 Conventional Vaccines
3.8 Recombinant Enzymes
3.8.1 Enterokinase
3.8.2 Cyclase
3.8.3 Caspase
3.8.4 Cathepsin
3.9 Cell and Gene Therapies
3.9.1 Allogenic Products
3.9.2 Autologous Products
3.9.3 Acellular Products
3.10 Synthetic Immunomodulators
3.11 Other Product Types
3.11.1 Blood Factors
3.11.2 Other Products
4 SEGMENTATION OF EUROPE MARKET BY TESTING SERVICE
4.1 Market Overview by Testing Service
4.2 Laboratory Testing
4.3 Custom Testing/Customer Proprietary Testing
4.4 Compendial and Multi Compendial Laboratory Testing
5 SEGMENTATION OF EUROPE MARKET BY RAW MATERIAL
5.1 Market Overview by Raw Material
5.2 Formulation Excipients
5.3 Active Pharmaceutical Ingredients (API)
5.4 Other Materials
6 SEGMENTATION OF EUROPE MARKET BY CLASSIFICATION
6.1 Market Overview by Classification
6.2 Innovative Biopharmaceuticals
6.3 Biogenerics and Biosimilars
7 SEGMENTATION OF EUROPE MARKET BY THERAPEUTIC AREA
7.1 Market Overview by Therapeutic Area
7.2 Oncology
7.3 Inflammatory and Infectious Diseases
7.4 Autoimmune Disorders
7.5 Metabolic Disorders
7.6 Hormonal Disorders
7.7 Cardiovascular Diseases
7.8 Neurological Diseases
7.9 Other Therapeutic Areas
8 EUROPEAN MARKET 2023-2033 BY COUNTRY
8.1 Overview of European Market
8.2 Germany
8.3 U.K.
8.4 France
8.5 Spain
8.6 Italy
8.7 Netherlands
8.8 Rest of European Market
9 COMPETITIVE LANDSCAPE
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
RELATED REPORTS
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary
2 MARKET OVERVIEW AND DYNAMICS
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.1.3 Impact of Russia-Ukraine Conflict
2.1.4 Impact of Israel-Palestine War
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis
3 SEGMENTATION OF EUROPE MARKET BY PRODUCT TYPE
3.1 Market Overview by Product Type
3.2 Monoclonal Antibodies
3.2.1 Anti-cancer Monoclonal Antibodies
3.2.2 Anti-inflammatory Monoclonal Antibodies
3.2.3 Other Monoclonal Antibodies
3.3 Recombinant Growth Factors
3.3.1 Erythropoietin
3.3.2 Granulocyte Colony Stimulating Factor
3.4 Purified Proteins
3.4.1 Leukemia Inhibitory Factor (LIF)
3.4.2 P53 Protein
3.4.3 P38 Protein
3.4.4 Other Purified Proteins
3.5 Recombinant Proteins
3.5.1 Serum Albumin
3.5.2 Amyloid Protein
3.5.3 Defensin
3.5.4 Transferrin
3.6 Recombinant Hormones
3.6.1 Recombinant Human Growth Hormones
3.6.2 Recombinant Insulin
3.6.3 Other Recombinant Hormones
3.7 Vaccines
3.7.1 Recombinant Vaccines
3.7.2 Conventional Vaccines
3.8 Recombinant Enzymes
3.8.1 Enterokinase
3.8.2 Cyclase
3.8.3 Caspase
3.8.4 Cathepsin
3.9 Cell and Gene Therapies
3.9.1 Allogenic Products
3.9.2 Autologous Products
3.9.3 Acellular Products
3.10 Synthetic Immunomodulators
3.11 Other Product Types
3.11.1 Blood Factors
3.11.2 Other Products
4 SEGMENTATION OF EUROPE MARKET BY TESTING SERVICE
4.1 Market Overview by Testing Service
4.2 Laboratory Testing
4.3 Custom Testing/Customer Proprietary Testing
4.4 Compendial and Multi Compendial Laboratory Testing
5 SEGMENTATION OF EUROPE MARKET BY RAW MATERIAL
5.1 Market Overview by Raw Material
5.2 Formulation Excipients
5.3 Active Pharmaceutical Ingredients (API)
5.4 Other Materials
6 SEGMENTATION OF EUROPE MARKET BY CLASSIFICATION
6.1 Market Overview by Classification
6.2 Innovative Biopharmaceuticals
6.3 Biogenerics and Biosimilars
7 SEGMENTATION OF EUROPE MARKET BY THERAPEUTIC AREA
7.1 Market Overview by Therapeutic Area
7.2 Oncology
7.3 Inflammatory and Infectious Diseases
7.4 Autoimmune Disorders
7.5 Metabolic Disorders
7.6 Hormonal Disorders
7.7 Cardiovascular Diseases
7.8 Neurological Diseases
7.9 Other Therapeutic Areas
8 EUROPEAN MARKET 2023-2033 BY COUNTRY
8.1 Overview of European Market
8.2 Germany
8.3 U.K.
8.4 France
8.5 Spain
8.6 Italy
8.7 Netherlands
8.8 Rest of European Market
9 COMPETITIVE LANDSCAPE
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
RELATED REPORTS
LIST OF TABLES
Table 1. Snapshot of Europe Biopharmaceuticals Market in Balanced Perspective, 2023-2033
Table 2. World Economic Outlook, 2024-2036
Table 3. World Economic Outlook, 2022-2024
Table 4. Scenarios for Economic Impact of Ukraine Crisis
Table 5. Scenarios for Economic Impact of Israel-Palestine War
Table 6. World Health Spending by Region, $ bn, 2013-2020
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021
Table 8. Worldwide Number of New Cancer by Type, 2020
Table 9. Main Product Trends and Market Opportunities in Europe Biopharmaceuticals Market
Table 10. Europe Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 11. Europe Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn
Table 12. Europe Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn
Table 13. Europe Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn
Table 14. Europe Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn
Table 15. Europe Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022
Table 17. Europe Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn
Table 18. Europe Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn
Table 19. Europe Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn
Table 20. Europe Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn
Table 21. Europe Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn
Table 22. Europe Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn
Table 23. Europe Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn
Table 24. Europe Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn
Table 25. Europe Biopharmaceuticals Market by Classification, 2023-2033, $ mn
Table 26. Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 27. Europe Biopharmaceuticals Market by Country, 2023-2033, $ mn
Table 28. Germany Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 29. Germany Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 30. U.K. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 31. U.K. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 32. France Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 33. France Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 34. Spain Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 35. Spain Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 36. Italy Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 37. Italy Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 38. Netherlands Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 39. Netherlands Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 40. Biopharmaceuticals Market in Rest of Europe by Country, 2023-2033, $ mn
Table 41. Abbott Laboratories: Company Snapshot
Table 42. Abbott Laboratories: Business Segmentation
Table 43. Abbott Laboratories: Product Portfolio
Table 1. Snapshot of Europe Biopharmaceuticals Market in Balanced Perspective, 2023-2033
Table 2. World Economic Outlook, 2024-2036
Table 3. World Economic Outlook, 2022-2024
Table 4. Scenarios for Economic Impact of Ukraine Crisis
Table 5. Scenarios for Economic Impact of Israel-Palestine War
Table 6. World Health Spending by Region, $ bn, 2013-2020
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021
Table 8. Worldwide Number of New Cancer by Type, 2020
Table 9. Main Product Trends and Market Opportunities in Europe Biopharmaceuticals Market
Table 10. Europe Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 11. Europe Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn
Table 12. Europe Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn
Table 13. Europe Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn
Table 14. Europe Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn
Table 15. Europe Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022
Table 17. Europe Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn
Table 18. Europe Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn
Table 19. Europe Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn
Table 20. Europe Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn
Table 21. Europe Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn
Table 22. Europe Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn
Table 23. Europe Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn
Table 24. Europe Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn
Table 25. Europe Biopharmaceuticals Market by Classification, 2023-2033, $ mn
Table 26. Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 27. Europe Biopharmaceuticals Market by Country, 2023-2033, $ mn
Table 28. Germany Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 29. Germany Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 30. U.K. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 31. U.K. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 32. France Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 33. France Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 34. Spain Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 35. Spain Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 36. Italy Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 37. Italy Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 38. Netherlands Biopharmaceuticals Market by Product Type, 2023-2033, $ mn
Table 39. Netherlands Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn
Table 40. Biopharmaceuticals Market in Rest of Europe by Country, 2023-2033, $ mn
Table 41. Abbott Laboratories: Company Snapshot
Table 42. Abbott Laboratories: Business Segmentation
Table 43. Abbott Laboratories: Product Portfolio
LIST OF FIGURES
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033
Figure 4. Europe Biopharmaceuticals Market, 2023-2033, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Europe Biopharmaceuticals Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022
Figure 10. Primary Restraints and Impact Factors of Europe Biopharmaceuticals Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Europe Biopharmaceuticals Market
Figure 13. Breakdown of Europe Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue
Figure 14. Europe Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%)
Figure 15. Europe Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn
Figure 16. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn
Figure 17. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn
Figure 18. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn
Figure 19. Europe Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn
Figure 20. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn
Figure 21. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn
Figure 22. Europe Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn
Figure 23. Europe Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn
Figure 24. Europe Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn
Figure 25. Europe Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn
Figure 26. Europe Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn
Figure 27. Europe Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn
Figure 28. Europe Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn
Figure 29. Europe Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn
Figure 30. Europe Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn
Figure 31. Europe Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn
Figure 32. Europe Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn
Figure 33. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn
Figure 34. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn
Figure 35. Europe Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn
Figure 36. Europe Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn
Figure 37. Europe Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn
Figure 38. Europe Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn
Figure 39. Europe Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn
Figure 40. Europe Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn
Figure 41. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn
Figure 42. Europe Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn
Figure 43. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn
Figure 44. Europe Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn
Figure 45. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn
Figure 46. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn
Figure 47. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn
Figure 48. Europe Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn
Figure 49. Europe Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn
Figure 50. Europe Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn
Figure 51. Europe Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn
Figure 52. Breakdown of Europe Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue
Figure 53. Europe Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%)
Figure 54. Europe Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn
Figure 55. Europe Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn
Figure 56. Europe Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn
Figure 57. Breakdown of Europe Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue
Figure 58. Europe Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%)
Figure 59. Europe Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn
Figure 60. Europe Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn
Figure 61. Europe Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn
Figure 62. Breakdown of Europe Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue
Figure 63. Europe Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%)
Figure 64. Europe Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn
Figure 65. Europe Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn
Figure 66. Breakdown of Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue
Figure 67. Europe Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 68. Europe Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn
Figure 69. Europe Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn
Figure 70. Europe Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn
Figure 71. Europe Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn
Figure 72. Europe Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn
Figure 73. Europe Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn
Figure 74. Europe Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn
Figure 75. Europe Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn
Figure 76. Breakdown of European Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue
Figure 77. Contribution to Europe 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 78. Biopharmaceuticals Market in Germany, 2023-2033, $ mn
Figure 79. Biopharmaceuticals Market in U.K., 2023-2033, $ mn
Figure 80. Biopharmaceuticals Market in France, 2023-2033, $ mn
Figure 81. Biopharmaceuticals Market in Spain, 2023-2033, $ mn
Figure 82. Biopharmaceuticals Market in Italy, 2023-2033, $ mn
Figure 83. Biopharmaceuticals Market in Netherlands, 2023-2033, $ mn
Figure 84. Biopharmaceuticals Market in Rest of Europe, 2023-2033, $ mn
Figure 85. Growth Stage of Europe Biopharmaceuticals Industry over the Forecast Period
Figure 86. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn
Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033
Figure 4. Europe Biopharmaceuticals Market, 2023-2033, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Europe Biopharmaceuticals Market
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022
Figure 10. Primary Restraints and Impact Factors of Europe Biopharmaceuticals Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of Europe Biopharmaceuticals Market
Figure 13. Breakdown of Europe Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue
Figure 14. Europe Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%)
Figure 15. Europe Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn
Figure 16. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn
Figure 17. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn
Figure 18. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn
Figure 19. Europe Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn
Figure 20. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn
Figure 21. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn
Figure 22. Europe Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn
Figure 23. Europe Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn
Figure 24. Europe Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn
Figure 25. Europe Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn
Figure 26. Europe Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn
Figure 27. Europe Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn
Figure 28. Europe Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn
Figure 29. Europe Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn
Figure 30. Europe Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn
Figure 31. Europe Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn
Figure 32. Europe Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn
Figure 33. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn
Figure 34. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn
Figure 35. Europe Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn
Figure 36. Europe Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn
Figure 37. Europe Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn
Figure 38. Europe Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn
Figure 39. Europe Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn
Figure 40. Europe Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn
Figure 41. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn
Figure 42. Europe Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn
Figure 43. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn
Figure 44. Europe Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn
Figure 45. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn
Figure 46. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn
Figure 47. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn
Figure 48. Europe Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn
Figure 49. Europe Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn
Figure 50. Europe Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn
Figure 51. Europe Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn
Figure 52. Breakdown of Europe Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue
Figure 53. Europe Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%)
Figure 54. Europe Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn
Figure 55. Europe Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn
Figure 56. Europe Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn
Figure 57. Breakdown of Europe Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue
Figure 58. Europe Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%)
Figure 59. Europe Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn
Figure 60. Europe Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn
Figure 61. Europe Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn
Figure 62. Breakdown of Europe Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue
Figure 63. Europe Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%)
Figure 64. Europe Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn
Figure 65. Europe Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn
Figure 66. Breakdown of Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue
Figure 67. Europe Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 68. Europe Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn
Figure 69. Europe Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn
Figure 70. Europe Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn
Figure 71. Europe Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn
Figure 72. Europe Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn
Figure 73. Europe Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn
Figure 74. Europe Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn
Figure 75. Europe Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn
Figure 76. Breakdown of European Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue
Figure 77. Contribution to Europe 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 78. Biopharmaceuticals Market in Germany, 2023-2033, $ mn
Figure 79. Biopharmaceuticals Market in U.K., 2023-2033, $ mn
Figure 80. Biopharmaceuticals Market in France, 2023-2033, $ mn
Figure 81. Biopharmaceuticals Market in Spain, 2023-2033, $ mn
Figure 82. Biopharmaceuticals Market in Italy, 2023-2033, $ mn
Figure 83. Biopharmaceuticals Market in Netherlands, 2023-2033, $ mn
Figure 84. Biopharmaceuticals Market in Rest of Europe, 2023-2033, $ mn
Figure 85. Growth Stage of Europe Biopharmaceuticals Industry over the Forecast Period
Figure 86. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn
